Allianz Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Allianz Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,500	Closed	-$428K	–	2070
2025 Q4	$428K	Buy	+5,500	New	+$371K	﹤0.01%	1853
2025 Q1	–	Sell	-9,600	Closed	-$386K	–	2295
2024 Q4	$386K	Buy	9,600 +1,000	+12%	+$45.2K	﹤0.01%	1935
2024 Q3	$407K	Buy	+8,600	New	+$380K	﹤0.01%	1907
2023 Q4	–	Sell	-13,200	Closed	-$183K	–	2194
2023 Q3	$183K	Hold	13,200	–	–	﹤0.01%	2128
2023 Q2	$303	Hold	13,200	–	–	﹤0.01%	2106
2023 Q1	$391K	Buy	+13,200	New	+$426K	﹤0.01%	1948
2022 Q3	–	Sell	-37,930	Closed	-$747K	–	2026
2022 Q2	$747K	Sell	37,930 -2,440	-6%	-$57K	﹤0.01%	1773
2022 Q1	$1.71M	Buy	+40,370	New	+$1.7M	﹤0.01%	1645

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Allianz Asset Management's KYMR Position: Q1 2026 in Review

Allianz Asset Management sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 5,500 shares — an estimated $428K sold.

Allianz Asset Management first reported a position in KYMR in Q1 2022 and held it in 8 quarters. The position peaked at $1.71M in Q1 2022. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

Allianz Asset Management reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
Allianz Asset Management sold 5,500 Kymera Therapeutics shares in Q1 2026, an estimated $428K.
Allianz Asset Management first reported a position in Kymera Therapeutics in Q1 2022 and held it in 8 quarters.
Allianz Asset Management's Kymera Therapeutics position peaked at $1.71M in Q1 2022.
256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.